Search

YoungEHA Mentorship Mixer at EHA2024

Hosted by the YoungEHA Committee, the Mentorship Mixer is a pilot event for a potential EHA mentorship program.

Read more

Recap: European Affairs and Hematology at EHA2024

As at previous congresses, the European Affairs track at EHA2024 offered opportunities to learn, exchange, and connect.

Read more

New at EHA 15: EHA-JSH Joint Symposium

On behalf of JSH Dr Toshiki Watanabe will speak about "Molecular pathogenesis of ATL". Dr Herman Einsele presents EHA with his lecture "New treatments strategies for EBV-associated LPD as a model for immunotherapy of virus-associated/induced tumors".

Read more

What to expect from European Affairs at EHA2024

European Affairs gives a voice to hematology professionals in Europe. The department ensures that the interests of EHA members are duly represented in policy, regulatory and scientific areas and networks.

Read more

Press Release: News on Red Cells and Iron presented at the 18th Congress of the European Hematology Asscociation in Stockholm June 13-16, 2013

Recent evidence suggests that these congenital anaemias are caused by molecular abnormalities in the transport of iron and other molecules and a deeper understanding of these mechanisms may lead to a better knowledge of the normal development of the red…

Read more

The invisible burden of the pandemic

Writing about my perspective on the COVID-19 pandemic has been on my mind for some time.

Read more

The Clot Thickens

Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).

Read more

Promising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more